Maze Therapeutics (MAZE) Fundamental Analysis: Revenue, Earnings & Valuation

7.13 / 10

Outperform

Fundamental analysis rates MAZE as Outperform with a 7.1/10 score. Strengths include high inventory turnover, solid accounts‑receivable turnover, strong interest coverage, and favorable Asset‑MV and Revenue‑MV differentials. Weak points are low fixed‑asset turnover and zero income‑tax‑to‑profit ratio, tempering the outlook.

Analysis Checks(8/10)

Revenue-MV

Value-0.28

Score3/3

Weight30.61%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value78.05

Score2/3

Weight1.63%

1M Return0.58%

Inventory turnover ratio

Value47.57

Score3/3

Weight-1.74%

1M Return-0.67%

Accounts receivable turnover ratio

Value25.89

Score2/3

Weight-1.72%

1M Return-0.65%

PB-ROE

Value1.63

Score2/3

Weight34.32%

1M Return8.98%

Income tax / Total profit (%)

Value0.00

Score0/3

Weight-3.91%

1M Return-1.54%

Fixed assets turnover ratio

Value7899.90

Score1/3

Weight-3.23%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-1.94%

1M Return-0.73%

Cost of sales ratio (%)

Value70.30

Score2/3

Weight-1.91%

1M Return-0.74%

Asset-MV

Value-0.48

Score3/3

Weight47.89%

1M Return13.09%

Is MAZE fundamentally strong?

MAZE scores 7.13/10 on fundamentals and holds a Discounted valuation at present. Backed by its -33.51% ROE, 0.00% net margin, -29.01 P/E ratio, 4.02 P/B ratio, and 87.80% earnings growth, these metrics solidify its Outperform investment rating.